NASDAQ:KYTX Kyverna Therapeutics (KYTX) Stock Price, News & Analysis $1.98 +0.01 (+0.51%) Closing price 04/4/2025 04:00 PM EasternExtended Trading$1.99 +0.01 (+0.45%) As of 04/4/2025 05:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Kyverna Therapeutics Stock (NASDAQ:KYTX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Kyverna Therapeutics alerts:Sign Up Key Stats Today's Range$1.86▼$2.0050-Day Range$1.93▼$3.5952-Week Range$1.86▼$24.91Volume334,476 shsAverage Volume430,481 shsMarket Capitalization$85.57 millionP/E RatioN/ADividend YieldN/APrice Target$18.33Consensus RatingBuy Company OverviewKyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.Read More… Remove Ads Kyverna Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks28th Percentile Overall ScoreKYTX MarketRank™: Kyverna Therapeutics scored higher than 28% of companies evaluated by MarketBeat, and ranked 793rd out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingKyverna Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageKyverna Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Kyverna Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Kyverna Therapeutics are expected to decrease in the coming year, from ($3.29) to ($3.73) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kyverna Therapeutics is -0.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Kyverna Therapeutics is -0.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Kyverna Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted14.62% of the float of Kyverna Therapeutics has been sold short.Short Interest Ratio / Days to CoverKyverna Therapeutics has a short interest ratio ("days to cover") of 8.1.Change versus previous monthShort interest in Kyverna Therapeutics has recently decreased by 5.90%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldKyverna Therapeutics does not currently pay a dividend.Dividend GrowthKyverna Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted14.62% of the float of Kyverna Therapeutics has been sold short.Short Interest Ratio / Days to CoverKyverna Therapeutics has a short interest ratio ("days to cover") of 8.1.Change versus previous monthShort interest in Kyverna Therapeutics has recently decreased by 5.90%, indicating that investor sentiment is improving significantly. News and Social Media1.7 / 5News Sentiment0.06 News SentimentKyverna Therapeutics has a news sentiment score of 0.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Kyverna Therapeutics this week, compared to 7 articles on an average week. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Kyverna Therapeutics insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 18.08% of the stock of Kyverna Therapeutics is held by institutions.Read more about Kyverna Therapeutics' insider trading history. Receive KYTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kyverna Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address KYTX Stock News HeadlinesKyverna Therapeutics price target lowered to $4 from $6 at H.C. WainwrightApril 4 at 8:16 AM | markets.businessinsider.comKyverna Therapeutics (KYTX) vs. The Competition Financial ComparisonApril 3 at 1:51 AM | americanbankingnews.comNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. April 5, 2025 | Porter & Company (Ad)Kyverna Therapeutics price target lowered to $20 from $40 at Morgan StanleyApril 2 at 7:39 PM | markets.businessinsider.comKyverna Therapeutics price target lowered to $12 from $13 at UBSMarch 29, 2025 | markets.businessinsider.comKyverna Therapeutics sees cash and securities sufficient into 2027March 29, 2025 | markets.businessinsider.comKyverna Therapeutics files $250M mixed securities shelfMarch 29, 2025 | markets.businessinsider.comKyverna Therapeutics Advances CAR T-Cell Therapy TrialsMarch 29, 2025 | tipranks.comSee More Headlines KYTX Stock Analysis - Frequently Asked Questions How have KYTX shares performed this year? Kyverna Therapeutics' stock was trading at $3.74 on January 1st, 2025. Since then, KYTX stock has decreased by 47.1% and is now trading at $1.98. View the best growth stocks for 2025 here. How were Kyverna Therapeutics' earnings last quarter? Kyverna Therapeutics, Inc. (NASDAQ:KYTX) issued its earnings results on Thursday, March, 27th. The company reported ($0.88) EPS for the quarter, missing analysts' consensus estimates of ($0.87) by $0.01. When did Kyverna Therapeutics IPO? Kyverna Therapeutics (KYTX) raised $319 million in an initial public offering on Thursday, February 8th 2024. The company issued 14,500,000 shares at a price of $22.00 per share. How do I buy shares of Kyverna Therapeutics? Shares of KYTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Kyverna Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Kyverna Therapeutics investors own include Tesla (TSLA), NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Alphabet (GOOG). Company Calendar Last Earnings3/27/2025Today4/05/2025Next Earnings (Estimated)5/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:KYTX Previous SymbolNASDAQ:KYTX CIK1994702 Webkyvernatx.com Phone510-626-8331FaxN/AEmployees96Year FoundedN/APrice Target and Rating Average Stock Price Target$18.33 High Stock Price Target$33.00 Low Stock Price Target$4.00 Potential Upside/Downside+825.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($3.47) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-60,370,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-51.12% Return on Assets-37.91% Debt Debt-to-Equity RatioN/A Current Ratio10.50 Quick Ratio10.50 Sales & Book Value Annual Sales$7.03 million Price / Sales12.17 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares43,215,000Free FloatN/AMarket Cap$85.57 million OptionableOptionable Beta2.57 Unlock the Potential in Options TradingOptions trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.Get This Free Report This page (NASDAQ:KYTX) was last updated on 4/5/2025 by MarketBeat.com Staff From Our Partners“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredBrace Yourself for Jeff Bezos’ “Amazon Helios”Jeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredIt’s Time to Buy Elon’s “ChatGPT Killer”Elon Musk’s new AI model is blowing everyone’s mind. It has been called “a game-changer in AI innovation”.....Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kyverna Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kyverna Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.